Published in Dig Dis Sci on October 01, 2006
A case report of de novo hepatocellular carcinoma after living donor liver transplantation. World J Surg Oncol (2013) 0.78
Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol (2015) 0.77
De novo Hepatocellular Carcinoma after Liver Transplantation. J Clin Transl Hepatol (2015) 0.75
Management of de novo hepatocellular carcinoma developing in a transplanted liver. Dig Dis Sci (2007) 0.75
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Increased cancer risk after liver transplantation: a population-based study. J Hepatol (2001) 2.25
Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl (2002) 2.00
Natural history of recurrent hepatitis C. Liver Transpl (2002) 1.49
De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl (2001) 1.30
Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl (2002) 1.03
Treatment of patients with hepatitis C and cirrhosis. Hepatology (2002) 1.02
De novo tumors after liver transplantation: a single-institution experience. Liver Transpl (2002) 1.00
Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl (2002) 0.97
Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol (2002) 0.97
Non-lymphoid cancer after liver transplantation. Hepatogastroenterology (1997) 0.94
Liver transplantation and hepatitis C. Transpl Int (2002) 0.92
Retransplantation for late liver graft failure: predictors of mortality. Liver Transpl (2000) 0.92
De novo hepatocellular carcinoma in a hepatic allograft with recurrent hepatitis C cirrhosis. Liver Transpl Surg (1999) 0.91
De novo tumors after orthotopic liver transplantation. Transplant Proc (2002) 0.90
Retransplantation for recurrent hepatitis C. Liver Transpl (2002) 0.87
Group G streptococcal bacteremia and de novo hepatocellular carcinoma after liver transplantation. Liver Transpl (2002) 0.82
Management of recurrent hepatitis C after liver transplantation. J Viral Hepat (2001) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05
Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology (2004) 2.54
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology (2006) 2.08
Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg (2003) 2.05
TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts. AJR Am J Roentgenol (2015) 1.99
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol (2007) 1.95
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol (2007) 1.77
The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J Immunol (2008) 1.75
Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73
Hepatic resection for primary hepatolithiasis: a single-center Western experience. J Am Coll Surg (2012) 1.70
Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl (2008) 1.68
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66
Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol (2013) 1.65
Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant (2003) 1.60
GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science (2013) 1.58
Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol (2004) 1.58
Medullary thymic epithelial cell depletion leads to autoimmune hepatitis. J Clin Invest (2013) 1.57
Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis (2009) 1.53
Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg (2015) 1.53
Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. J Hepatol (2013) 1.52
Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol (2002) 1.52
Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol (2007) 1.51
Lymphoplasmacytic sclerosing pancreatitis: inflammatory mimic of pancreatic carcinoma. J Gastrointest Surg (2003) 1.49
Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology (2009) 1.48
The beneficial impact of temporary porto-caval shunt in orthotopic liver transplantation: a single center analysis. Transpl Int (2010) 1.48
Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46
Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl (2004) 1.44
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology (2005) 1.44
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43
Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. Eur J Gastroenterol Hepatol (2014) 1.40
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol (2009) 1.39
Biologic predictors of survival in node-negative gastric cancer. Ann Surg (2003) 1.37
Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg (2004) 1.36
Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest (2010) 1.23
Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J Hepatol (2005) 1.21
Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on "Surgical Misinterpretation" of the BCLC Staging System. Ann Surg (2015) 1.17
Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant (2004) 1.17
Molecular genetics of hepatocellular neoplasia. Am J Transl Res (2010) 1.16
A comprehensive, case-based review of groove pancreatitis. Pancreas (2009) 1.15
An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis (2004) 1.15
Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol (2010) 1.15
A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl (2005) 1.13
Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost (2004) 1.12
Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09
Feasibility and preliminary accuracy of high-resolution imaging of the liver and pancreas using FNA compatible microendoscopy (with video). Gastrointest Endosc (2012) 1.09
Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor. Cardiovasc Pathol (2008) 1.09
Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl (2007) 1.08
Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery (2007) 1.07
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
Hilar cholangiocarcinoma involving the portal vein bifurcation: long-term results after resection. J Hepatobiliary Pancreat Surg (2002) 1.03
Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol (2007) 1.03
Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl (2009) 1.02
A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation. Ann Surg (2007) 1.02
Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience. Am J Surg (2008) 1.02
Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology (2012) 1.01